Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

General Pharmaceutical Council issues new guidance following reports people are lying about their weight in online forms and submitting photos of themselves in baggy clothes ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

marketed as Ozempic pre-filled pen and Rybelsus oral tablet for T2D and as Wegovy injection for weight management. Wegovy is a significant contributor to Novo Nordisk's revenues. Despite supply ...

Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock Two health technology startups have an idea for treating obesity: Use genetic tests and other tests to see whether expensive weight ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...